(Q37785949)

23 August 2017

title

Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. (English)

1 reference

23 August 2017

0 references

0 references

1 reference

1 reference

3

Merlin L Robb

1 reference

23 August 2017

4

Nelson L Michael

1 reference

23 August 2017

2

Jerome H Kim

1 reference

23 August 2017

Robert M Paris

1

1 reference

23 August 2017

publication date

1 September 2010

1 reference

Expert Review of Vaccines

23 August 2017

published in

1 reference

23 August 2017

volume

9

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

1055-1069

1 reference

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Failure of the Merck HIV vaccine: an uncertain step forward.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Vaccines: correlates of vaccine-induced immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Challenges in the development of an HIV-1 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

The rational design of an AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

The challenge of HIV-1 subtype diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

HIV vaccine design and the neutralizing antibody problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

A whole-genome association study of major determinants for host control of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Host determinants of HIV-1 control in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

HIV and SIV CTL escape: implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

DNA vaccines: developing new strategies to enhance immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

21 January 2018

The science of adjuvants

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Macaques vaccinated with live-attenuated SIV control replication of heterologous virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Vaccinia virus: a tool for research and vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Mucosal vaccines: the promise and the challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Acceptability of A-CASI by HIV-positive IDUs in a multisite, randomized, controlled trial of behavioral intervention (INSPIRE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV inf

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Safety profile of recombinant canarypox HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Fowlpox virus as a vector in non-avian species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

GP120: target for neutralizing HIV-1 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Recognition of escape variants in ELISPOT does not always predict CD8+ T-cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

A systematic comparison of methods to measure HIV-1 specific CD8 T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Different Vaccine Vectors Delivering the Same Antigen Elicit CD8+ T Cell Responses with Distinct Clonotype and Epitope Specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

The immune response during acute HIV-1 infection: clues for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Founder Effects in the Assessment of HIV Polymorphisms and HLA Allele Associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Evolution and transmission of stable CTL escape mutations in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Genomewide Association Study of an AIDS‐Nonprogression Cohort Emphasizes the Role Played byHLAGenes (ANRS Genomewide Association Study 02)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIV‐1 Vaccine Candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

Antibody to Haemophilus influenzae type b after routine and catch-up vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.106

21 January 2018

Identifiers

DOI

10.1586/ERV.10.106

1 reference

23 August 2017

1 reference